|
US5981481A
(en)
|
1974-12-06 |
1999-11-09 |
The Johns Hopkins University |
Human C3b/C4b receptor (CR1)
|
|
US5212071A
(en)
|
1988-04-01 |
1993-05-18 |
The Johns Hopkins University |
Nucleic acids encoding a human C3b/C4b receptor (CR1)
|
|
US4454151A
(en)
|
1982-03-22 |
1984-06-12 |
Syntex (U.S.A.) Inc. |
Use of pyrrolo pyrroles in treatment of ophthalmic diseases
|
|
US4943529A
(en)
|
1982-05-19 |
1990-07-24 |
Gist-Brocades Nv |
Kluyveromyces as a host strain
|
|
AU3145184A
(en)
|
1983-08-16 |
1985-02-21 |
Zymogenetics Inc. |
High expression of foreign genes in schizosaccharomyces pombe
|
|
US4879231A
(en)
|
1984-10-30 |
1989-11-07 |
Phillips Petroleum Company |
Transformation of yeasts of the genus pichia
|
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
|
JPH0742235B2
(ja)
|
1985-11-08 |
1995-05-10 |
三共株式会社 |
自己免疫性疾病の予防・治療剤
|
|
GB8610600D0
(en)
|
1986-04-30 |
1986-06-04 |
Novo Industri As |
Transformation of trichoderma
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US5733254A
(en)
|
1987-10-15 |
1998-03-31 |
Cypress Bioscience, Inc. |
Method for treating patients suffering from immune thrombocytopenic purpura
|
|
US5256642A
(en)
|
1988-04-01 |
1993-10-26 |
The Johns Hopkins University |
Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
|
|
DE3830271A1
(de)
|
1988-09-06 |
1990-03-15 |
Goetze Otto |
Mittel mit immunsuppressiver wirkung
|
|
ATE189526T1
(de)
|
1988-10-28 |
2000-02-15 |
Genentech Inc |
Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
|
|
US5328470A
(en)
|
1989-03-31 |
1994-07-12 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
|
DE394538T1
(de)
|
1989-04-28 |
1991-04-11 |
Rhein Biotech Ges. Fuer Biotechnologische Prozesse Und Produkte Mbh, 4000 Duesseldorf |
Hefezellen der schwanniomyces-gattung.
|
|
EP0402226A1
(en)
|
1989-06-06 |
1990-12-12 |
Institut National De La Recherche Agronomique |
Transformation vectors for yeast yarrowia
|
|
FR2648133B1
(fr)
|
1989-06-08 |
1992-02-21 |
Sanofi Sa |
Lauramides n-substitues, leur preparation et compositions les contenant
|
|
FR2649120B1
(fr)
|
1989-06-30 |
1994-01-28 |
Cayla |
Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
|
|
US5331090A
(en)
|
1989-09-08 |
1994-07-19 |
California Institute Of Biological Research |
CR2 ligand compositions and methods for modulating immune cell functions
|
|
US5310729A
(en)
|
1990-04-20 |
1994-05-10 |
California Institute Of Biological Research |
Interferon-related polypeptides as CR2 ligands and their use for modulating immune cell functions
|
|
US6458360B1
(en)
|
1990-04-25 |
2002-10-01 |
The Johns Hopkins University |
Soluble complement regulatory molecules
|
|
KR0185215B1
(ko)
|
1990-11-30 |
1999-05-01 |
요시다 쇼오지 |
서방성 안구삽입용 약제
|
|
EP0512733A2
(en)
|
1991-05-03 |
1992-11-11 |
Washington University |
Modified complement system regulator
|
|
US5178635A
(en)
|
1992-05-04 |
1993-01-12 |
Allergan, Inc. |
Method for determining amount of medication in an implantable device
|
|
DE4222534A1
(de)
|
1992-07-09 |
1994-01-13 |
Behringwerke Ag |
Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
|
|
US5679546A
(en)
|
1993-09-24 |
1997-10-21 |
Cytomed, Inc. |
Chimeric proteins which block complement activation
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5679345A
(en)
|
1994-06-02 |
1997-10-21 |
The Johns Hopkins University |
Method for preventing complement-dependent rejection of organ or tissue transplants
|
|
NZ295352A
(en)
|
1994-10-25 |
1999-09-29 |
Glaxo Group Ltd |
Use of binding agents like antibodies for inhibiting cd23 in treating prophylaxis of autoimmune diseases
|
|
US5922320A
(en)
|
1996-06-14 |
1999-07-13 |
Georgetown University |
Recombinant proCVF
|
|
US5843778A
(en)
|
1996-06-14 |
1998-12-01 |
The Johns Hopkins University School Of Medicine |
Use of chimeric vaccinia virus complement control proteins to inhibit complement
|
|
CA2263838A1
(en)
|
1996-08-21 |
1998-02-26 |
Sugen, Inc. |
Crystal structures of a protein tyrosine kinase
|
|
US6214966B1
(en)
|
1996-09-26 |
2001-04-10 |
Shearwater Corporation |
Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
|
|
GB9624731D0
(en)
|
1996-11-28 |
1997-01-15 |
Univ Leicester |
Complement inhibitor
|
|
WO1999002567A2
(en)
|
1997-07-08 |
1999-01-21 |
Board Of Regents, The University Of Texas System |
Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
|
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
WO1999037149A1
(en)
|
1998-01-27 |
1999-07-29 |
Brigham & Women's Hospital |
Methods of treating cytotoxic damage
|
|
DE69939813D1
(de)
|
1998-02-20 |
2008-12-11 |
Tanox Inc |
Inhibitoren der komplement-aktivierung
|
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
|
WO1999044625A1
(en)
|
1998-03-03 |
1999-09-10 |
John Hopkins University |
Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
|
|
JP5138844B2
(ja)
|
1998-06-12 |
2013-02-06 |
ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド |
抗原およびEBVGp350/220の受容体の同時刺激によるB細胞活性化および免疫グロブリン分泌の増強
|
|
US6572856B1
(en)
|
1998-09-10 |
2003-06-03 |
The University Of Virginia Patent Foundation |
Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
|
|
EP1001021B1
(en)
|
1998-09-25 |
2003-08-27 |
Wolfgang Prodinger |
Monoclonal antibody to human CD21, and its uses
|
|
US6224866B1
(en)
|
1998-10-07 |
2001-05-01 |
Biocrystal Ltd. |
Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
|
|
ATE352559T1
(de)
|
1998-12-08 |
2007-02-15 |
Biovation Ltd |
Verfahren zur verminderung der immunogenität von proteinen
|
|
WO2000040749A2
(en)
|
1999-01-06 |
2000-07-13 |
Genenews Inc. |
Method for the detection of gene transcripts in blood and uses thereof
|
|
US6943153B1
(en)
|
1999-03-15 |
2005-09-13 |
The Regents Of The University Of California |
Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
|
|
KR20020027311A
(ko)
|
1999-05-07 |
2002-04-13 |
제넨테크, 인크. |
B 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
|
|
US7282562B2
(en)
|
1999-08-31 |
2007-10-16 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US6331313B1
(en)
|
1999-10-22 |
2001-12-18 |
Oculex Pharmaceticals, Inc. |
Controlled-release biocompatible ocular drug delivery implant devices and methods
|
|
GB0008582D0
(en)
|
2000-04-08 |
2000-05-31 |
Adprotech Plc |
DNA immunization vectors
|
|
EP2026073B1
(en)
|
2000-04-29 |
2016-03-30 |
University Of Iowa Research Foundation |
Diagnostics and therapeutics for macular degeneration-related disorders
|
|
US7439330B2
(en)
|
2000-05-08 |
2008-10-21 |
President And Fellows Of Harvard College |
Anti-glycated CD59 antibodies and uses thereof
|
|
CN1592645A
(zh)
|
2000-09-18 |
2005-03-09 |
拜奥根Idec公司 |
使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
|
|
US7122181B2
(en)
|
2000-12-19 |
2006-10-17 |
Research Development Foundation |
Lentiviral vector-mediated gene transfer and uses thereof
|
|
WO2002068579A2
(en)
|
2001-01-10 |
2002-09-06 |
Pe Corporation (Ny) |
Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
|
|
US7645739B2
(en)
|
2001-02-21 |
2010-01-12 |
Alavita Pharmaceuticals, Inc. |
Modified annexin compositions and methods of using same
|
|
EP1839670A3
(en)
|
2001-02-21 |
2009-11-11 |
Alavita Pharmaceuticals, Inc. |
Modified Annexin Proteins and their use against thrombosis
|
|
US7635676B2
(en)
|
2001-02-21 |
2009-12-22 |
Alavita Pharmaccuticals, Inc. |
Modified annexin proteins and methods for their use in organ transplantation
|
|
US7635680B2
(en)
|
2001-02-21 |
2009-12-22 |
Alavita Pharmaceuticals, Inc. |
Attenuation of reperfusion injury
|
|
US6820011B2
(en)
|
2001-04-11 |
2004-11-16 |
The Regents Of The University Of Colorado |
Three-dimensional structure of complement receptor type 2 and uses thereof
|
|
CN1511041A
(zh)
|
2001-05-17 |
2004-07-07 |
������ҩ������˾ |
利用抑制cd21的药剂治疗抗体介导的病变的方法
|
|
US20030181531A1
(en)
|
2003-02-11 |
2003-09-25 |
David Sherris |
Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
|
|
WO2003018774A2
(en)
|
2001-08-29 |
2003-03-06 |
University Of Virginia Patent Foundation |
Therapeutic uses of complement receptor 2
|
|
US20030129164A1
(en)
|
2001-12-03 |
2003-07-10 |
Flannery John G. |
Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
|
|
EP1336618A1
(en)
|
2002-02-15 |
2003-08-20 |
HANS-KNÖLL-INSTITUT FÜR NATURSTOFF-FORSCHUNG e.V. |
Porcine complement regulator factor H and its use
|
|
US20030180292A1
(en)
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
|
WO2003077796A2
(en)
|
2002-03-15 |
2003-09-25 |
University Of Southern California |
Ophthalmic solutions for delivery of expression vectors
|
|
US20040058313A1
(en)
|
2002-04-24 |
2004-03-25 |
Abreu Marcio Marc |
Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
|
|
EP2292259A3
(en)
|
2002-11-15 |
2011-03-23 |
MUSC Foundation For Research Development |
Complement receptor 2 targeted complement modulators
|
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
CN1791422A
(zh)
|
2003-03-28 |
2006-06-21 |
应用研究系统Ars股份公司 |
凝聚素在治疗和/或预防周围神经疾病中的用途
|
|
US20070123466A1
(en)
|
2003-05-13 |
2007-05-31 |
New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery |
Method of treating recurrent miscarriages
|
|
JP4029772B2
(ja)
|
2003-05-16 |
2008-01-09 |
株式会社日立製作所 |
磁気ヘッドおよびそれを用いた磁気記録再生装置
|
|
EP1488798A1
(en)
|
2003-06-18 |
2004-12-22 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
|
|
JP4818917B2
(ja)
|
2003-08-08 |
2011-11-16 |
イミューノメディクス、インコーポレイテッド |
腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体
|
|
EP1682179A4
(en)
|
2003-11-05 |
2008-09-03 |
Palingen Inc |
IMPROVED B-CELL CYTOTOXICITY OF CDIM BINDING ANTIBODY
|
|
US8454963B2
(en)
|
2003-11-13 |
2013-06-04 |
Musc Foundation For Research Development |
Tissue targeted complement modulators
|
|
CA2554729A1
(en)
|
2004-01-27 |
2005-08-11 |
University Of Southern California |
Polymer-bound antibody cancer therapeutic agent
|
|
DK1713503T3
(da)
|
2004-02-10 |
2013-11-04 |
Univ Colorado Regents |
Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
|
|
EP1713503B1
(en)
|
2004-02-10 |
2013-07-31 |
The Regents of the University of Colorado, a Body Corporate |
Inhibition of factor b, the alternative complement pathway and methods related thereto
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
EP1797118A2
(en)
|
2004-09-03 |
2007-06-20 |
Creabilis Therapeutics S.P.A. |
Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
US7423128B2
(en)
|
2004-11-03 |
2008-09-09 |
Amgen Fremont Inc. |
Anti-properdin antibodies, and methods for making and using same
|
|
WO2006062716A2
(en)
|
2004-11-18 |
2006-06-15 |
Yale University |
Methods and compositions for treating ocular disorders
|
|
WO2006083533A2
(en)
|
2005-01-14 |
2006-08-10 |
The Regents Of The University Of California |
Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
|
|
EP2357257B1
(en)
|
2005-02-14 |
2019-07-31 |
University of Iowa Research Foundation |
Methods and reagents for treatment and diagnosis of age-related macular degeneration
|
|
ES2548700T3
(es)
|
2005-05-26 |
2015-10-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
|
|
US20090087907A1
(en)
|
2005-07-29 |
2009-04-02 |
Alice Pebay |
Compositions and Methods for Growth of Pluripotent Cells
|
|
CN101262855A
(zh)
|
2005-09-08 |
2008-09-10 |
帝斯曼知识产权资产管理有限公司 |
治疗或预防年龄相关性黄斑变性的方法
|
|
AU2006292132A1
(en)
|
2005-09-19 |
2007-03-29 |
Palingen, Inc. |
Treatment of B cell diseases using anti-germline antibody binding agents
|
|
ES2551202T5
(es)
|
2005-11-04 |
2018-11-30 |
Genentech, Inc. |
Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
|
|
US20110014270A1
(en)
|
2006-03-27 |
2011-01-20 |
The Regents Of The University Of Colorado |
Prevention and treatment of ischemia-reperfusion injury and related conditions
|
|
GEP20125628B
(en)
|
2006-04-21 |
2012-09-10 |
Novartis Ag |
Pharmaceutical compositions containing antagonist anti-cd40 antibody
|
|
EP1854810A1
(en)
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
|
|
AU2007261315B2
(en)
|
2006-06-21 |
2012-10-25 |
Musc Foundation For Research Development |
Targeting complement factor H for treatment of diseases
|
|
US7705475B2
(en)
|
2006-08-03 |
2010-04-27 |
Stats Chippac Ltd. |
Integrated circuit package system
|
|
CN106084054A
(zh)
|
2006-11-02 |
2016-11-09 |
健泰科生物技术公司 |
人源化的抗‑d因子抗体
|
|
AU2008251943B2
(en)
*
|
2007-03-14 |
2013-09-05 |
Alexion Pharmaceuticals, Inc. |
Humaneered anti-factor B antibody
|
|
AU2008262048B2
(en)
|
2007-06-07 |
2013-09-26 |
Genentech, Inc. |
C3b antibodies and methods for the prevention and treatment of complement- associated disorders
|
|
AU2008293487A1
(en)
|
2007-08-27 |
2009-03-05 |
Novelmed Therapeutics, Inc. |
Method of inhibiting complement activation with factor Bb specific antibodies
|
|
PE20091388A1
(es)
|
2007-11-02 |
2009-09-24 |
Novartis Ag |
Moleculas y metodos para modular el componente de complemento
|
|
ES2538114T3
(es)
|
2008-03-03 |
2015-06-17 |
Novelmed Therapeutics, Inc. |
Anticuerpos anti-properdina
|
|
WO2010015608A1
(en)
|
2008-08-05 |
2010-02-11 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
|
EP2358392B1
(en)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antibody formulation
|
|
US8840868B2
(en)
|
2009-02-04 |
2014-09-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles
|
|
US20100291106A1
(en)
|
2009-05-06 |
2010-11-18 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c3b
|
|
US9291622B2
(en)
|
2009-05-21 |
2016-03-22 |
Apellis Pharmaceuticals, Inc. |
Complement assays and uses thereof
|
|
AU2010266127B2
(en)
*
|
2009-07-02 |
2015-11-05 |
Musc Foundation For Research Development |
Methods of stimulating liver regeneration
|
|
EA201290286A1
(ru)
|
2009-11-05 |
2013-01-30 |
Алексион Кембридж Корпорейшн |
Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
|
|
SG185483A1
(en)
|
2010-05-14 |
2012-12-28 |
Univ Colorado Regents |
Improved complement receptor 2 (cr2) targeting groups
|
|
EP2585110A4
(en)
|
2010-06-22 |
2014-01-22 |
Univ Colorado Regents |
ANTIBODIES AGAINST THE C3D FRAGMENT OF THE COMPLEMENT COMPONENT 3
|
|
CN103248395A
(zh)
|
2012-02-09 |
2013-08-14 |
中兴通讯股份有限公司 |
一种窄带干扰抑制方法及装置
|
|
US9803005B2
(en)
|
2012-05-24 |
2017-10-31 |
Alexion Pharmaceuticals, Inc. |
Humaneered anti-factor B antibody
|